OpenAI released LifeSciBench on Thursday, a first-of-its-kind expert-written benchmark designed to measure how well agentic AI systems perform real-world life science research tasks, rather than narrow, structured biology trivia. The benchmark addresses a long-standing gap in AI evaluation for scientific use cases.
LifeSciBench includes 750 tasks spanning seven core life science research workflows, created and reviewed by 173 Ph.D.-level scientists with direct biotech and pharmaceutical industry experience. It grades responses on scientific accuracy, practical research usefulness, and adherence to expert expectations for collaborative scientific work, not just whether a model produces a correct final answer.
LifeSciBench targets flaws in existing life science AI benchmarks
Current life science AI evaluations overwhelmingly focus on narrow, isolated skills such as fact recall, molecular property prediction, or multiple-choice question answering, with structured formats and clean reference answers that do not reflect the ambiguity, incomplete evidence, and multi-step reasoning required for actual applied research. OpenAI designed LifeSciBench to close this gap by modeling every task after a request a practicing scientist would give to a knowledgeable collaborator, per the company’s official announcement [1].
Benchmark structure mirrors real research workflows
The benchmark’s task taxonomy was built from surveys of practicing life scientists about their most common applied research activities, grouped into seven recurring categories: evidence handling, analysis, design and optimization, scientific reasoning, validation and operations, translation, and scientific communication. Of the 750 total tasks, 79% require multiple reasoning or decision-making steps, with an average of four steps per task. More than half (53%) require models to interpret or synthesize information from at least one attached artifact, including figures, PDFs, tables, sequence files, chemical structures, or web references, for a total of 1,062 artifacts across the full benchmark [1].
For example, one high-complexity task asks models to prepare a critical review of a regulatory submission package for AAV9-microDys-X, an AAV9-based micro-dystrophin gene therapy for Duchenne muscular dystrophy. The task requires synthesizing pre- and post-treatment Western blot data from a 12-patient Phase 1b/2 trial, clinical context about the 4–7 year old ambulatory patient population, and FDA precedent for surrogate endpoints to evaluate whether the package supports accelerated approval [1].
Expert review and rubrics prioritize scientific nuance over binary correctness
All tasks were created by 173 expert scientists with Ph.D.-level training and direct experience advancing drug discovery programs in biotech or pharmaceutical settings. Each task underwent an unlimited number of revision cycles before acceptance, with accepted tasks averaging six self-directed automated review cycles and at least two rounds of expert review. All reviews were anchored to either a verifiable correct answer or strong expert consensus, with a 90% agreement threshold required among domain reviewers for task acceptance. A total of 453 expert reviewers contributed to the validation process [1].
Grading uses task-specific rubrics with an average of 25 criteria per task, for a total of 19,020 rubric points across the full benchmark.
The rubrics are designed to mirror how scientific work is evaluated in practice: a response may reach the correct high-level conclusion but still be marked incomplete if it overlooks a key assay limitation or fails to proactively flag a highly consequential biological nuance.
The rubric design also accounts for the uncertainty inherent to real research: many tasks do not have a single “correct” answer, but instead require models to make justifiable judgments based on incomplete or conflicting evidence, a skill current benchmarks rarely test.
Conversely, a partially complete response with high-quality reasoning may still earn partial credit, even if it does not fully solve the task [1].
LifeSciBench arrives as labs race to build useful scientific AI
The benchmark’s release coincides with a wave of recent research from OpenAI and other labs focused on building agentic AI systems that can contribute to end-to-end scientific research, rather than just answering isolated questions. Earlier this week, OpenAI published research showing a GPT-5.4-powered agentic system paired with Molecule.one’s Maria lab automation platform improved Chan-Lam coupling yields for primary sulfonamides by more than 80% across tested substrates, a reaction class that has historically produced low yields for medicinal chemists working on oncology, infectious disease, and other therapeutic areas [2].
Unlike narrow benchmarks that test single skills such as protein folding prediction or multiple-choice biology trivia, LifeSciBench is designed to measure whether models can handle the full complexity of life science research, from interpreting conflicting experimental data to communicating conclusions that are useful for regulatory or research decision-making. The benchmark’s release follows OpenAI’s recent introduction of GPT-Rosalind, a purpose-built model for life sciences research and drug discovery workflows [2].
Bottom line: LifeSciBench gives life science research teams and AI developers a concrete, expert-validated framework to evaluate whether agentic AI systems can contribute to real, multi-step research workflows, rather than just performing well on narrow, structured biology benchmarks.
